Oncotelic’s Intranasal Brain Delivery Platform Highlighted as CNS Drug Development Gains Urgency
Oncotelic Therapeutics featured in BioMedWire editorial for its nose-to-brain delivery platform that bypasses the blood-brain barrier, with rising Alzheimer’s cases and biodefense needs driving demand for such technologies.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) was featured in a BioMedWire editorial that examines the growing urgency around effective central nervous system (CNS) drug delivery, highlighting the company’s proprietary intranasal nose-to-brain (N2B) delivery platform designed to bypass the blood-brain barrier and deliver therapeutics directly to the brain. The editorial notes that rising global Alzheimer’s cases and increased biodefense focus are major catalysts driving demand for faster, more targeted CNS delivery technologies.
The coverage positions Oncotelic’s platform-based approach as part of a broader shift toward delivery innovation as a critical determinant of therapeutic success. It also places Oncotelic alongside major biopharma and advanced therapeutics players including Amgen (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV) and Lunai Bioworks (NASDAQ: LNAI), underscoring continued momentum across next-generation treatment development.
BioMedWire notes that Oncotelic’s strategy combines platform scalability with monetization opportunities, including its agreement with Lunai involving defined applications for its N2B delivery technology. This model aims to address both commercial CNS indications and high-priority biodefense applications, reflecting a dual-use approach that could accelerate development timelines and expand market reach.
The editorial points to the broader context of CNS drug development, where delivery remains a primary bottleneck. The blood-brain barrier prevents approximately 98% of small-molecule drugs and nearly all large-molecule therapeutics from reaching the brain, making platforms that can overcome this barrier highly valuable. Oncotelic’s intranasal approach offers a non-invasive alternative to traditional methods such as injections or implants, potentially improving patient compliance and enabling repeated dosing.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. It also leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens its position in oncology and rare disease therapeutics.
The full press release is available at https://ibn.fm/wTLMS. For the latest news and updates relating to OTLC, visit the company’s newsroom at https://ibn.fm/OTLC.